-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 23, the Insight database showed that Hengrui Medicine launched a phase III clinical trial to explore the combination of PD-L1/TGFβ bifunctional fusion protein SHR-1701 combined with chemotherapy and bevacizumab-like drug BP102 as the first-line treatment for cervical cancer
From: Insight database (http://db.
In November, SHR-1701 has successively launched 3 late-stage clinical trials, including a phase II/III clinical phase for perioperative treatment of gastric cancer, a phase III clinical phase for non-squamous non-small cell lung cancer, and the first-line treatment just announced Phase III clinical of cervical cancer
SHR-1701 domestic phase III and phase II/III clinical
From Insight database (http://db.
SHR-1701 is an anti-PD-L1/TGF-βRII bifunctional fusion protein independently developed by Hengrui Medicine.
According to the Insight database, the drug is advancing rapidly, and it was first reported for clinical trials in 2018, and clinical trials started in the same year
SHR-1701 project time axis
From: Insight database (http://db.
At the 2021 ESMO conference, Hengrui has announced the cervical cancer expansion cohort (cohort4) data of SHR-1701 for advanced solid tumor phase I (Abstract number: 776P, clinical trial registration number: NCT03774979)
As of February 26, 2021, the median exposure time of SHR-1701 was 12 weeks (3.
Hengrui's SHR-1701 is the second PD-L1/TGFβ dual-target drug in the world's research and development progress, and the first is Merck's M7824
The results showed that the ORR assessed by RECIST v1.
The published clinical data has preliminarily confirmed the therapeutic potential of PD-(L)1/TGFβ drugs in the field of cervical cancer.
The popularity of the target combination of PD-L1/TGFβ is well known, and now at least 12 domestic enterprise projects have entered the clinical stage
Progress of new domestic drugs for PD-(L)1/TGFβ
From Insight database (http://db.